Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay P Garg

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Seminars in Nephrology|June 25, 2016
Targeting Cell Death Pathways for Therapeutic Intervention in Kidney DiseasesJay P Garg, Domagoj Vucic
Vascular Medicine (London, England)|June 27, 2002
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular diseaseJay P Garg, George L Bakris
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|April 14, 2005
Bone disease and bottle capsMegan Tichy, Jay P Garg, Kerry C Cho, et al.
American Journal of Hypertension|May 11, 2005
Resistant hypertension revisited: a comparison of two university-based cohortsJay P Garg, William J Elliott, Amy Folker, et al.
Clinical Pharmacology in Drug Development|March 17, 2017
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK InhibitorTong Zhu, Corrie Howieson, Tomasz Wojtkowski, et al.
Arthritis and Rheumatism|January 11, 2005
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trialJay P Garg, Scott Chasan-Taber, Andrew Blair, et al.
Clinical Pharmacokinetics|November 24, 2016
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy SubjectsTong Zhu, Barbara Parker, Tomasz Wojtkowski, et al.
American Journal of Nephrology|August 10, 2005
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot studyJay P Garg, Renee Ellis, William J Elliott, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 10, 2023
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY TrialBrad H Rovin, Richard A Furie, Jorge A Ross Terres, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid ArthritisMark C Genovese, Maria Greenwald, Christine Codding, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Seminars in Nephrology|June 25, 2016
Targeting Cell Death Pathways for Therapeutic Intervention in Kidney DiseasesJay P Garg, Domagoj Vucic
Vascular Medicine (London, England)|June 27, 2002
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular diseaseJay P Garg, George L Bakris
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|April 14, 2005
Bone disease and bottle capsMegan Tichy, Jay P Garg, Kerry C Cho, et al.
American Journal of Hypertension|May 11, 2005
Resistant hypertension revisited: a comparison of two university-based cohortsJay P Garg, William J Elliott, Amy Folker, et al.
Clinical Pharmacology in Drug Development|March 17, 2017
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK InhibitorTong Zhu, Corrie Howieson, Tomasz Wojtkowski, et al.
Arthritis and Rheumatism|January 11, 2005
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trialJay P Garg, Scott Chasan-Taber, Andrew Blair, et al.
Clinical Pharmacokinetics|November 24, 2016
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy SubjectsTong Zhu, Barbara Parker, Tomasz Wojtkowski, et al.
American Journal of Nephrology|August 10, 2005
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot studyJay P Garg, Renee Ellis, William J Elliott, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 10, 2023
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY TrialBrad H Rovin, Richard A Furie, Jorge A Ross Terres, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid ArthritisMark C Genovese, Maria Greenwald, Christine Codding, et al.
Pageof 2